TRIP13 overexpression is a driver of B-cell malignancies28 and is functionally linked to drug resistance in multiple myeloma and other cancers30, and inhibition of TRIP13 is toxic to multiple myeloma cells54. Here, TRIP13 is linked to AL amyloidosis.